N
Google TrendMATTHEW STONE SR (200+) — Adult victims, suspected shooter ID'd in Erie mass shooting
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:matthew stone sr200+selma blair2000+al-nassr vs neftchi fergana5000+samantha busch500+crimson rescued mountain lion cub500+peggy flanagan200+sean combs10000+boeing 747500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Developing Small-Molecule" (30 stories)

Top Headline Story

Purdue small-molecule inhibitors shown to promote robust antitumor immunity
Lead StoryPurdue Universityworld
Aug 24

Purdue small-molecule inhibitors shown to promote robust antitumor immunity

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQV3NsZ2Y4dU5TQlBzMFNnRnlhaUp5NG5HWldiQ1hJMHczTzQxNm55UUhuWlBFU3NlTjBicXBQOVZobTRTQ1R1QWI4ZldsQlRMZmVWbUNNTTQ1UWxHam0tcGxUamdXQ2Q0VGd5YUNUSjF6eDJPVFdJUzg5QjlWZXdlZXBleVdtN1NJMHZ1Vm1EcHZSall0Q3plYVNCY0lqNWN1VDQ4TVRlU1FPcU9EcHlTMlBCUWFCQQ?oc=5" target="_blank">Purdue small-molecule inhibitors shown to promote robust antitumor immunity</a>  <font color="#6f6f6f">Purdue University</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
200+18m ago

matthew stone sr

Adult victims, suspected shooter ID'd in Erie mass shooting

Filter stories
2000+38m ago

selma blair

Selma Blair Arrested, Attacks Flight Crew After Trying to Open Plane Door Mid-Air

Filter stories
5000+48m ago

al-nassr vs neftchi fergana

Al Nassr Asian Champions League clash in doubt over Riyadh security situation

Filter stories
500+48m ago

samantha busch

Brexton Busch honors dad Kyle with burnout, signature bow

Filter stories

Search Results for "Developing Small-Molecule"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Why Drug Development Still Lacks Integration
The Medicine Makergeneral

Why Drug Development Still Lacks Integration

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPZ0JabGxPZElZWjRkaExwWHBpdUJadmozWVhndWhKYl83Z3F4VlZXZ29WV0lkNDJBZWFmWVJsREhSNW5xNkdTSWpSRXd6aEl6MG1Rck5kUmxBYjhoSHhrUFlaYk1jcXhpaTEzMDJ6cEt2S1ZoMEltd3c5RHRadGVfck96S21kMkk4ZzZ6ZF92M000dHJhaXFVZk9zcmhvYklraFE?oc=5" target="_blank">Why Drug Development Still Lacks Integration</a>  <font color="#6f6f6f">The Medicine Maker</font>

Read Full StoryMore like this
When does the molecule emerge from the column?
Chemeuropegeneral

When does the molecule emerge from the column?

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQZ3dlMThVRXBDVDk2ZWs0STJHenF6VktWOUFfX3hlSThJUncyMlBzbXZxaGZrbnRaQmczU1BZX0VNcGpkZGxTb0pYdUwtZUdVWlFRU1lLTkxmRXRzNE5mS01BcW80ZUx5Z2QxcGlDdlNhZFNYUWdFVEV0bFJkdGVmZzV3dEh4Wjk0N2lzU0tteEh3YlhtUVNEUw?oc=5" target="_blank">When does the molecule emerge from the column?</a>  <font color="#6f6f6f">Chemeurope</font>

Read Full StoryMore like this
Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30
PR Newswiregeneral

Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30

<a href="https://news.google.com/rss/articles/CBMixwJBVV95cUxOaTREbjA0ZTdRcm5iemhlRmd3WEQxbWotU1FJRTRuOW1QRXg1N2tBaU84OFZJVzZyMThRUGtmdkl3dWlrUGN6LVlzZzJKUmtsZVJrZW94eklnc3cySkNHOFVpTVhBYVd2VnhmdnIybXRQMElWckFQSjZHeWFOZ3pReUs5LXhVVDQtVEpzWERGUXJOdTZTVG1qWEF2bHNfY3YwUjRDSTljRUZLT1o1X1BTODB6SHpXVXU1MjMyTkFyMHZablp6RUtXaXRjQU1vNkFIdVFwTWw4dHpHQkJpSDBlMlE4TnBZcXNQbmh4Y1RSRDNtYkg1MnpOcGZlS0s0bmxjbWh6U0J4bGVUUnJDRW1rSGJnVk4yVmNuWi1XbGhyWHZaRk9YSl8xWVBwem1jdVNxWUFNR3BfR0VYZXBXNXhBYWxRbk5XU2M?oc=5" target="_blank">Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Moving beyond the binary: how the convergence of small and large molecules is reshaping pharmaceutical R&D
Drug Discovery & Developmentgeneral

Moving beyond the binary: how the convergence of small and large molecules is reshaping pharmaceutical R&D

<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxQeGUxRGxXN0J6bXpZOHk3SUFRSFRVOUF5OUxqaDB6MS03YVRaZ2E5T3BpSjdtYjNMY2l5YnpORVljLUU5RU5jUEpoT3pqeC1nNlJxckxDVXI0c0RjWDJPb2x1eUpxMTAtRjJ2OXlPcTBRckZoOUVEbVdZREtoY3B3RTl1bUQtcVBobUw4ajVoU1U4WmxsMTVlVUJWNy1CbGxVeXFXSlg1Y2lZQU5ZMV9BcElSWEdYbVRCVVh5TVJVS2RCYWVpRVc3R3RYRDhRc3QyMVZ1cjROMlM?oc=5" target="_blank">Moving beyond the binary: how the convergence of small and large molecules is reshaping pharmaceutical R&D</a>  <font color="#6f6f6f">Drug Discovery & Development</font>

Read Full StoryMore like this
Chemify and Sanacor Collaborate to Discover and Develop Small Molecule Therapies for Cardiometabolic Diseases
Business Wiregeneral

Chemify and Sanacor Collaborate to Discover and Develop Small Molecule Therapies for Cardiometabolic Diseases

<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxPQmtQblhQUWNCa2VBd3JPSC1LNjBfemZHNFVaRmlPN19hZ19PQzJOUHFrYl9mdnlockVoN1d5dEQtOWNGdnRpemhtY0xJbFA3WGJLQXdJSk5PUGxFdXFsREtCaGpUTmhlT29ROUExRGZCWkJaUWR4UDVjQW8yYnRKTlZQcHpaX0R6MjdzT0RUbThESnNSWk5ta1g1VmNMYzdqVnA0b3lVU1JjQ0V3MTBwb2JySW9oY05XY0NLTEkyRzNVY2F3TlNQZ0loVzk2UTNET3FiMnZNNkdFT3V3dXRjMUEzZXZ5YUVUXzd0VkludEtJTjl4cFN2R3FR?oc=5" target="_blank">Chemify and Sanacor Collaborate to Discover and Develop Small Molecule Therapies for Cardiometabolic Diseases</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
AI Can Accelerate Discovery — Development Still Decides What Advances
MedCity Newstech

AI Can Accelerate Discovery — Development Still Decides What Advances

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPWW8yQnVibEkwa3lhUFk3QU9sNk9NVW1ScXQwaUVydC0zSjRtM2tWTHNib0R4R2hmVmRXeFVrOExoQmRKT3RTNEFES3JEVmVFM0ZLY3RqN1NGMXd4aWhuckp0QlFmcExwVEhjLWstT1ZCZkdScmUyYjlCN04yc09TRGZRVFNlOVNielAtVW91Y3lTbnVfNC1wendZLVM0ZnFVSGc?oc=5" target="_blank">AI Can Accelerate Discovery — Development Still Decides What Advances</a>  <font color="#6f6f6f">MedCity News</font>

Read Full StoryMore like this
From Molecules to Medicines: How Drug Development Evolved and Why It’s More Complex Than Ever
Applied Clinical Trials Onlinegeneral

From Molecules to Medicines: How Drug Development Evolved and Why It’s More Complex Than Ever

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxQVy1Xa1lCRm9hc2NXRjQwN1JHYjdHNTN4T29FSVZwVjNfZnlyU0tkMXZIQjJnODBCYW1TWFVadGVKbTEtZnVRTjM3dURGRTZ5QVR2UklBcEswLUhmVTVzNzY5c1U3MlJ6ZmtSelNhY1MwaDM4M2NVS0VISENDTjZnaGZjVmJPMnVrblNMTG9R?oc=5" target="_blank">From Molecules to Medicines: How Drug Development Evolved and Why It’s More Complex Than Ever</a>  <font color="#6f6f6f">Applied Clinical Trials Online</font>

Read Full StoryMore like this
Acelot Announces Initiation of Dosing in Phase Ia Clinical Trial of ACE-2223, a First-in-Class Oral Small Molecule Targeting Aggregated TDP-43 in Amyotrophic Lateral Sclerosis (ALS)
BioSpaceworld

Acelot Announces Initiation of Dosing in Phase Ia Clinical Trial of ACE-2223, a First-in-Class Oral Small Molecule Targeting Aggregated TDP-43 in Amyotrophic Lateral Sclerosis (ALS)

<a href="https://news.google.com/rss/articles/CBMivwJBVV95cUxPbnljRTV3azIxWTJDcG5OOFBtbUxmNE5zcllIbDlib05Yd1AwVC1WUGp4X2NXaTh3bF91ak1qOWlrT1ZCSUxzM2V3bTU1V1JybGJmRHVKcWQ3ODNyRGdGdVY2dWFKdDZHSlhpa0xuMG92QVVzZVRDVTNOMkY0NmlhcHozdzdqYzkxRjlpbXk0NUlEb21PNERWbklTVExPUUllcjBBYXdJMkU5azF3YS01bVpVSzQ1ZS1jM2prT3g0TzBUb0d4UDRpU1Jvcm1WenFwYkRKMnEyQ0gtNXVzbzMyVGlQYko1N0RVSVdUWVZ1Z3pYbnlvSFNEa1NFQ1U1V0tId0EyYTRIY0R3WUdrNUhrbTE4TzZmLUplWllseHE0amhNV1puTS0tbF84VkNLT1h5NWtueGZXaGE4ZGVBckdR?oc=5" target="_blank">Acelot Announces Initiation of Dosing in Phase Ia Clinical Trial of ACE-2223, a First-in-Class Oral Small Molecule Targeting Aggregated TDP-43 in Amyotrophic Lateral Sclerosis (ALS)</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Transcripta Bio Raises $24M for AI-Driven Neurological Disease Therapies
Genetic Engineering and Biotechnology Newstech

Transcripta Bio Raises $24M for AI-Driven Neurological Disease Therapies

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxOTmZfX2k0T2wzMlE1Yjk2bXhZY1NLclU3ZDJIbFk3ZHNGOUxlSElmclNqN05Pb1p0SnN1b3gyYkY2VG1fcFhCOUhMQlBPNWpTZFZXcDdQRFU1ZFNtM2lucU5mdDF3RnRJOHVqeGxzZTRienJNMmE3V1AxdjZJS2l2ZHY3YkNWNVNSa2VEckRpc19SMTM3MEZZcWNBQk1GOF9WT1o3MW8tSnFYZXdkRXBJM05NckpxdkcxNy1GSDVlWkVDOWdfY1gtZ2ZR?oc=5" target="_blank">Transcripta Bio Raises $24M for AI-Driven Neurological Disease Therapies</a>  <font color="#6f6f6f">Genetic Engineering and Biotechnology News</font>

Read Full StoryMore like this
Niagen Selects Evotec to Advance Preclinical Development of Oral Small-Molecule Candidate
Contract Pharmageneral

Niagen Selects Evotec to Advance Preclinical Development of Oral Small-Molecule Candidate

<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxQN0V5cTlQX3VNZG1nUnhMM0RnckZZMWx1dnJhTk9RZXMwSnNSMVo3NVJNdHNfczdDWnZ2aFFzN2RuT2dvd2VVMWphTUNXTE9Yc2F2NHlCdXMwY0FvZXdKNHNYdUxXSVpiM1FKbzBCckw1MzRkWGhvZURUclNJenhiNG5wYTJ5cVpITENLWkIzZVNOd2xkdmhrZHBuSW9oSWU5LWJ5MjhHNDUyemJjQ3ZKVllGRW1HTHBlR01mVnpUTUk4U0tUWVY3cVVnVWZVYUJJ?oc=5" target="_blank">Niagen Selects Evotec to Advance Preclinical Development of Oral Small-Molecule Candidate</a>  <font color="#6f6f6f">Contract Pharma</font>

Read Full StoryMore like this
Small-molecule degraders for oncogenic KRAS
Naturegeneral

Small-molecule degraders for oncogenic KRAS

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBRSnk1YnFDWXVLSnNGMXRmS1lqVWxTdFlTQTZNSVFaVnRCb2ZqWXA4SXI2VnRZd3ZaNlhfTE1LY0hpOW9qaUxuYkF3Zlp6R3N0R0VKZ21TdjB6Smo2UWd3?oc=5" target="_blank">Small-molecule degraders for oncogenic KRAS</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
GSK to buy cancer drug developer Nuvalent for $10.6 billion
Chemical & Engineering Newspolitics

GSK to buy cancer drug developer Nuvalent for $10.6 billion

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPVGs5VExQZVF0ME1DeHI5eFBxUDNnelZRX0lmVlhoV0RCSEhLOUlXOE1XVVBjcVBsNURXVnh3UkpDWW1XWnNPSDBKNUJPNXNWUkNHYndtdk1tSFc5NlRxaVNJZk42Qk9uUlk0UW5lc2J3Mm1kdHpTUEt6VDFvbENsR2tPSUI4TDRVM19GOHlrQm13NEppeVZWX0hxUThDZEVtd3Vn?oc=5" target="_blank">GSK to buy cancer drug developer Nuvalent for $10.6 billion</a>  <font color="#6f6f6f">Chemical & Engineering News</font>

Read Full StoryMore like this
How Can a Novel Small Molecule Manage a Unique Multiple Myeloma Subtype?
CancerNetworkworld

How Can a Novel Small Molecule Manage a Unique Multiple Myeloma Subtype?

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPRmVZQXBBQzhKLXVEM2pURms1N2JIamN6YTJ0QjBIa29BSmFzdXZTcHBQUHF3ZWNNdTRKVHlBRnZsdmQyTWVyZlplNTNvS2pfOEY5Qzlud2NZVzh2NC1YbFg2dmNBYll4Nnc3X0lvbm5CVXI2eHBHaU04OW1NQXVOMkxsUjZQQ2p4ZjBTRHV6eVRMUXExd1M1a1dEVU9pY2Y1aTl0ZE5SU2VyUXc?oc=5" target="_blank">How Can a Novel Small Molecule Manage a Unique Multiple Myeloma Subtype?</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
A Small Molecular Module Helps Time Development | Newswise
Newswisegeneral

A Small Molecular Module Helps Time Development | Newswise

<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxONU9Cc2Jka2VvTkFQMTdCYy13WVd5dVpBQ0pzdGZkYXBCUEZNeTR3b0wtZmFvMExvMExmd2djM3VRVVM4Z2g1S1JfWTBQdzlqcEpZajl5eFA3S3FpUTc3ZDM5cW13NV85YnRBemMzSE9RSW5FR3VSb3pnb3RTUGt4aGJQb0NfR2Fr0gGIAUFVX3lxTE41T0JzYmRrZW9OQVAxN0JjLXdZV3l1WkFDSnN0ZmRhcEJQRk15NHdvTC1mYW8wTG8wTGZ3Z2MzdVFVUzhnaDVLUl9ZMFB3OWpwSllqOXl4UDdLcWlRNzdkMzlxbXc1XzlidEF6YzNIT1FJbkVHdVJvemdvdFNQa3hoYlBvQ19HYWs?oc=5" target="_blank">A Small Molecular Module Helps Time Development | Newswise</a>  <font color="#6f6f6f">Newswise</font>

Read Full StoryMore like this
Almirall Enters Collaboration With CrystalO for the Discovery and Development of Novel Small Molecules in Medical Dermatology
Business Wiregeneral

Almirall Enters Collaboration With CrystalO for the Discovery and Development of Novel Small Molecules in Medical Dermatology

<a href="https://news.google.com/rss/articles/CBMijwJBVV95cUxQNFkwc0dhaTB2VXJSQmRUWFV5cWRYT0pVT0FjbFdIOUt4dzJDMU1CZm1TVFlSdTB1ZnlYTUFtckZ4OVNUVlViUDB2MTRiaGQ5YkRmWU5NRU90UnM5QlBMNVA2WXdoYW5jaGJ5dXhpeXBLRVRMRkxMOHRfX1pCb2k0dWhhYmpFQTYxR0xJVEVBOUtnbDA3dnZsMUlQRVNOQWJlcUtBTC0xWWVZbGNFci1wTDljWnlHSnZJWWZQWF9MNmVBWjZWYjBvNHZDajY5d1J2ZENNbm9WeER2TzFrWktrcGpXanIzajNYNk1jaVpzWUNIM0NwVmJxdm4tSU5XM19hd3FVLTVHdHNNQ0ZfRmJN?oc=5" target="_blank">Almirall Enters Collaboration With CrystalO for the Discovery and Development of Novel Small Molecules in Medical Dermatology</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization
PR Newswiretech

Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization

<a href="https://news.google.com/rss/articles/CBMiuAJBVV95cUxQdUNURHNaaHpjbWFsbk5tQ05JOERhWWRDQzNoN1RINDJVeWxWUVpYQjhzMWhRSGpiTDNraUo5Tnh3Z3k1TU9YM0tLck1wWVVnUEZwQVlMdW1fdFdVamM3VHBoQTkwclRqa3NRblAzVGctUEFHbVBmZDRoQWthYllyLXdDVTF3aVo0LWlZMUtGQl9rbDBpZnZ1VFlQRGFKbG5mT2lEMUw1bU1fcWNXVjRVQjc1cnhIcWlTYkJweDlRVFl6cDNnTjNya1Mxb2R3T0FFZUFCd2RPVldJU0gzb0d3QU96OGotQ3pzODhpcHA1MmJ6MWJiVWZjenhiNjBmNWhNSkpCNnhuM0tpNmZ5bGxoQnZ3akRVS0g4eFdvakdoczRra19PWnlhY0ZLOVh3UWF3aWtVSkRJbWk?oc=5" target="_blank">Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Sling Therapeutics Announces $123 Million Series C Financing to Advance Phase 3 Development of its Oral Small Molecule IGF-1R Inhibitor for Thyroid Eye Disease
Business Wireworld

Sling Therapeutics Announces $123 Million Series C Financing to Advance Phase 3 Development of its Oral Small Molecule IGF-1R Inhibitor for Thyroid Eye Disease

<a href="https://news.google.com/rss/articles/CBMivwJBVV95cUxPWTdyZ1AzNTIxQkpkT1ZRMlN2TmFRQW9nV3dhSjZJSzJDMWpNYnB4Yzdtc3diLXVlSVIydXhsYVJLZjhhWWJHTVZGNWtFdkh5aVkzR1Vzay1TYjk1TUNNX2F4cnhHMHVQVVExUnZtd1ZGUUpQWDlpUzFLbENTZ1h3WElmcUlJa1pkNmpDSEprcWJTWE02VGpDMTlWb2FXeGlhaEc0WWh6RGNGNnVjeDBudEJhNFgwRFB1elgxdDlJQUtQTjVSUVVKMklQTWh6NW1kNWJHU0VHYUtRTkx0N1VJRzlZbWtlWTZUNml3QVJfcDF4SnNjOHBhSEhCWnljWmlya0dtak1ScW5qSlBWOVNCcDNyVlkyOEllYWNyRVBkYTgtcFVhMDNtbVlNWExGdUR4WG1FamdrbmxuZ1FjZHFV?oc=5" target="_blank">Sling Therapeutics Announces $123 Million Series C Financing to Advance Phase 3 Development of its Oral Small Molecule IGF-1R Inhibitor for Thyroid Eye Disease</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
SynSmart and Amporin Announce Collaboration to Develop Breakthrough Small Molecule Therapeutics for Degenerative Diseases
Business Wireworld

SynSmart and Amporin Announce Collaboration to Develop Breakthrough Small Molecule Therapeutics for Degenerative Diseases

<a href="https://news.google.com/rss/articles/CBMiigJBVV95cUxPX0lNZG9qSnBJS3JBQV9DSFpteVlkY2hmNFBGMUZtQmJhMGZEZzUtMkh0TDBnYzVtMFFmdk84cnZoTGNKQkx2NGp6QTBVZmVFWmZfREhpZk1DMVY5bTBYQ1lxQ3ZJOUp0ZHpwb3FTVHZUYVZzcHRRZFFiU2k0bTdtMmQ3dkZ1WDVSZEZxX2hxUHhzMGZyck02MnZOM0RhcEZKU2pOaHk1cDhkY0kzY2lsQ1g5WWdTeURjMzFEVDBJc3BHaDlCWUlOUkNNc05RczE3dTd6S1B2U1pLYjFKdEdPSmQxdXRhb3NGd2pHRnM2ZWlGRXVXY1oxQmI1ak1JcXFaMHU5U1p2TzF2QQ?oc=5" target="_blank">SynSmart and Amporin Announce Collaboration to Develop Breakthrough Small Molecule Therapeutics for Degenerative Diseases</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
PR Newswiretech

Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development

<a href="https://news.google.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?oc=5" target="_blank">Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
How small molecule tau inhibitors could treat Alzheimer’s disease
Drug Discovery Newsgeneral

How small molecule tau inhibitors could treat Alzheimer’s disease

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPZlE2aTFXOWJkS3NGUjkwaG5VbTV6cEJtT2Nhc2hheFdnYjI0N2ZxeC1mTzl2a1M1ZDFfWFZNajRTN1QtajZOdEZ4QlZJa1hhVDlUU19zbXFYTnVsd1RKU0dHOW5DZXhHVXZKcFY3aEh1eXhocVNoUUVrelVwQUF0NFJXd2c1QlJNLXdyZndiS3hpZVp4WFpoa080ckxQQk51UTUyVGNhTFI?oc=5" target="_blank">How small molecule tau inhibitors could treat Alzheimer’s disease</a>  <font color="#6f6f6f">Drug Discovery News</font>

Read Full StoryMore like this
Excelsior raises $95 million to rethink small-molecule chemistry for the AI era
Drug Discovery Newstech

Excelsior raises $95 million to rethink small-molecule chemistry for the AI era

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQdHFsR2F2MkUtVFB4Vlh6T1I5cUFRZk1rS0ZDOVcydmZaMjFlakxBZkstbHJuUG5uQ29FbW9BX2tJQmNkd1VxUDhkV1FJQXVPNlEtQm4tWElNYnNsWWxEb1l1OERhd3dKMkJTckM2WC02cVdEWmNHYUV2T0xmT21LOFgxTGlzM2Q1aEFvSmFSZmp3YUk1N3lpbUxyVW1EZUJCa3pSTzgyTU5SdldUaTkxYjRTTGNqMjdMSnlV?oc=5" target="_blank">Excelsior raises $95 million to rethink small-molecule chemistry for the AI era</a>  <font color="#6f6f6f">Drug Discovery News</font>

Read Full StoryMore like this
Iambi Enters $1.7 Billion Collaboration with Takeda Advancing Small Molecule Programs
Pharmaceutical Executivepolitics

Iambi Enters $1.7 Billion Collaboration with Takeda Advancing Small Molecule Programs

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPRnVpLVJvSU5Ta1NBVU1jRzFqQ01YQWRuQU1lVkhSd2EyeVpMVi1HSjVaYTZ2ei1faXdDWnY5Wlk0ZXBETWdabkw1dzM0SWNycEV5b0o5V1BuSWlpYV9TNWQzT3pvbkJYZXRCRExtbEpuZmdaMkNHZFVPVTRIMEJjTnVpYUZmVXgydFE0OEFXQVpEbncwRjFyX0lFZlNVU2d3UXotZnRzdjduZ3o5emZoVjNOTQ?oc=5" target="_blank">Iambi Enters $1.7 Billion Collaboration with Takeda Advancing Small Molecule Programs</a>  <font color="#6f6f6f">Pharmaceutical Executive</font>

Read Full StoryMore like this
Excelsior Sciences raises $95 million to speed small molecule drug development using AI
Reuterstech

Excelsior Sciences raises $95 million to speed small molecule drug development using AI

<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxObC1DZkxpcGN6QlFJenRTellhZUNMZU5PV3JFRDAyWlZKUmtCSVBkRUl2YXFiNHZSLVpQRW9mSlQ4SmVUcjFaZnpwMjQ2Y1ZtQTlVbk5MN1oxbEJQaU9CTDRkZDM0NzBEWXNQYmV2RUpmU2tpWVN0ZVlGa1JRS0lHbVZzVFR5Y1otY2xEc05iYVZkakVVUTdpNURqYnVvZkpXRHNQdkVLcjFpVUpuWlQ5WENTdEFnajdzeDNmTk9aWVFXM1diZjNfczBmMmJOTU5oYnNoU2dLSUZXQVdxNlpWdDFDbldoZ1U?oc=5" target="_blank">Excelsior Sciences raises $95 million to speed small molecule drug development using AI</a>  <font color="#6f6f6f">Reuters</font>

Read Full StoryMore like this
Investor Webinar – 15 October 2026 – Company Announcement
Financial Timesworld

Investor Webinar – 15 October 2026 – Company Announcement

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxPZjd0ZDMtYy14c1lsZzFET21vSXl6V3lDdVQya0RrOHJValg5Y3RTWTBlYkZKcG5xeVIteDhXa1R5S0RScjFaY2tST2x0dktmMVZXNEdQQnlLMDJXYjZ1N2JiZmZiTmw0VGYybmlVaXRrUVh0THRIOHctWTVsY3VkVDlqRHduSmJIV0pzZ1h2cnlfWDg?oc=5" target="_blank">Investor Webinar – 15 October 2026 – Company Announcement</a>  <font color="#6f6f6f">Financial Times</font>

Read Full StoryMore like this
Small Molecules to Big Partnership: Incyte, Genesis Expand AI Collaboration to $1B+
Genetic Engineering and Biotechnology Newstech

Small Molecules to Big Partnership: Incyte, Genesis Expand AI Collaboration to $1B+

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQWVkyU3l1WEE4TTlpQjZEcnRaZV96SnB2TGRMY1NLYWxqTFBnN29xa1BxS0EydzFQLXNleEFfaWVodlFTbFRLV0xUbG9VRVljVzN4Q1hiWXVMVHpYNXR5elllcER3aXp6aHRGWjlpWmI4aUtUUkJpVzVfUFAxSHdNSkhOeGJ5N2ZUVVVMQ2J6YmlVTFQwSDVWekhuYXJMQ3VTM2tLWGdhcnFhV3dKWGRlTlUwVTU3NnJyem1WT25RY1Q2VzE1SkdyWHhkUWkzazR1RldyMw?oc=5" target="_blank">Small Molecules to Big Partnership: Incyte, Genesis Expand AI Collaboration to $1B+</a>  <font color="#6f6f6f">Genetic Engineering and Biotechnology News</font>

Read Full StoryMore like this
Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies
Insilico Medicinegeneral

Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies

<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxPRmtYZ3FyQmJ6WGplejNCTUJ2Q1ktcnc4Sk1TRk5WWGp0STBxUDY0ZFIzMGt6ajJPUmNVcUNkQW9sYmtDb05FZ3FycXhqQXNFVGF1VDJmWHlUa1NkeDZBSVNxaXQ3ZDRpMDVEZVJ5dzV2aFFuNW1HMHFLNjZxR3c4UTZDUQ?oc=5" target="_blank">Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies</a>  <font color="#6f6f6f">Insilico Medicine</font>

Read Full StoryMore like this
Considerations for establishing occupational exposure limits for small molecule kinase inhibitors in drug development
Frontiersgeneral

Considerations for establishing occupational exposure limits for small molecule kinase inhibitors in drug development

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxPSDdIb3AxclNHNkxzak9kcjFqVFNCRWZpYklyaXJWWVY5ZFQwYy1CRUlFUkhfUzhBbHZTc21BbHZqd01qMm5xS1hnWENzeGNGTVR1V2xOUWtRbnhVUGJCTEFGSkxYWllTUTVtTG42d0FvbzMzNHJoUjdzVXllbkpCLTd3UHlQQldvc1FodFFwSmk?oc=5" target="_blank">Considerations for establishing occupational exposure limits for small molecule kinase inhibitors in drug development</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Molly Gibson: Superintelligence and the Future of Drug Development
Inside Precision Medicinegeneral

Molly Gibson: Superintelligence and the Future of Drug Development

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxOV05aTmRzOTM3YWtUU2xTZjVBd0lMOW9xZjhhalNBLUdCTWJxMjNzVUN3bnRKLUxjQTlRcTJoYkpHZGU2UV9KeDdxUWw3czZ0LUJGZ2lSOUZmZWJIeEJqOFNRTTdYYk16aU1IQ0VoMWV1LUljSlBjWUJaQkNpRUhSVEw1RmdibU9LOHFVbTJBbVZrS2E4ODhlRzZUZFVIM2ZYUVZvQ25LWjUxdl9VanhkQW16eXVHcGZMZG9tNTdsdG9YQW8?oc=5" target="_blank">Molly Gibson: Superintelligence and the Future of Drug Development</a>  <font color="#6f6f6f">Inside Precision Medicine</font>

Read Full StoryMore like this
Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate
BioSpacescience

Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate

<a href="https://news.google.com/rss/articles/CBMiqgJBVV95cUxOVDBPdUF6dHdhVWZfOGF0U0pVeTBfVGpUSWlqemtMeGJRckhiWlZLQWVNcFRieC1MU3VYYkliUHFsSFNBM1hJUEFWZUpnaERmRlVDa2N3YlUyRHQ2VW1HWUZWbUd1Vl9QaHJ0eDMzNUU0ak1FNGNIdzN3N3BnSUg1ZzdJcWZzNE9qXzNLdVJVUFZzUG4tVVVvTVlJRDVaTEhuQTlsak42bkVBSFBLMmQ1RXY3WUF3QlVnY3ZaTGMtV2I5cjdLM3FNWFdObGVua3BKVG02SEcwUU9WaURkNzBwVm53WFVhRGs4cEZQS0JrWmhJcVZpbUdxeloxTDB3aFp2a0g4WTU0UGIzTjhMeEpKUlN3T2RucWJ1SDZLcXlGalgwcWVDRVNjTEFB?oc=5" target="_blank">Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
"Developing Small-Molecule" — Live Google News Trends & Headlines